L&C Bio (290650) Fundamentals 2026 — Revenue Analysis | SniperIQ
L&C Bio (290650) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩1.50T, trading at ₩61000.00 on the KOE. This SniperIQ fundamentals page covers L&C Bio's valuation, profitability (net margin -137.8%), revenue (₩85.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is L&C Bio's market cap?
L&C Bio (290650) has a market capitalization of approximately ₩1.50T, trading at ₩61000.00 on the KOE. Market cap moves with the live share price.
What is L&C Bio's P/E ratio?
L&C Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is L&C Bio?
L&C Bio runs a net profit margin of -137.8%, a gross margin of 54.6%, and an operating margin of 10.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does L&C Bio generate?
L&C Bio reported revenue of ₩85.5B for fiscal year 2025, with net income of -₩138.2B and earnings per share (EPS) of -5811.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does L&C Bio pay a dividend?
L&C Bio offers a trailing dividend yield of about 0.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is L&C Bio financially healthy?
L&C Bio carries a debt-to-equity ratio of 0.43x and a current ratio of 0.64x, with a market beta of 1.36. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is L&C Bio a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For L&C Bio (290650) the key facts are: market cap ₩1.50T, revenue ₩85.5B, 52-week range 29100-125000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track L&C Bio's full fundamentals live
Get L&C Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.